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Antihypertensive therapy in a model combining spontaneous hyperten-
sion with diabetes. We have compared the effects of the angiotensin
converting enzyme inhibitor, perindopril, and a conventional antihyper-
tensive regimen (triple therapy: hydralazine, reserpine and hydrochlo-
rothiazide) on kidney function and albuminuria in hypertensive diabetic
rats. Diabetes was induced with streptozotocin in spontaneously hyper-
tensive (SHR) rats and they were randomized to receive no treatment,
perindopril or triple therapy. Antihypertensive drugs were commenced
at the time of induction of diabetes and continued for 16 weeks. Blood
pressure reduction was equal in the groups treated with perindopril or
triple therapy. All groups had similar severity of diabetes as determined
by body weight, serum glucose and glycated hemoglobin levels.
Whereas plasma renin activity rose in both the perindopril and triple
therapy groups, it is likely that the effects on angiotensin 11 levels were
opposite since perindopril but not triple therapy was associated with a
significant reduction in plasma angiotensin converting enzyme activity.
Diabetes was associated with an increase in glomerular filtration rate.
At 12 weeks, glomerular filtration rate was higher in the perindopril
treated group when compared to the triple therapy group, but neither
group treated with antihypertensive therapy was different to untreated
diabetic rats. Both drug regimens reduced albuminuria in the diabetic
rats to a similar degree apparently independently of their effects on the
renin-angiotensin system. Studies in diabetic subjects are warranted to
evaluate different classes of antihypertensive drugs with respect to their
effects on kidney function, proteinuria and glomerular morphology.
It has been suggested that certain classes of antihypertensive
agents may be of specific benefit in retarding the progression of
renal disorders such as diabetic nephropathy [1]. Previous
studies by our group have suggested that hypertension is an
important accelerator of both functional and structural features
of diabetic nephropathy [21. The most sensitive marker of these
changes has been the dramatic increase in urinary albumin
excretion observed in diabetic hypertensive rats. This increase
is approximately tenfold when compared to normotensive dia-
betic rats studied over a similar period of time. Recently, we
have reported a comparison between the ACE inhibitor, enal-
april and the conventional antihypertensive regimen, hydrala-
zinc and metroprolol, in diabetic spontaneously hypertensive
rats (SHR) [31. These two antihypertensive regimens were
equivalent in efficacy in retarding the rate of increase in
albuminuria as well as reducing glomerular volume and glomer-
ular basement thickness. However, since metoprolol is a beta
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blocker which may itself suppress the renin-angiotensin system
[4] it was difficult to determine from that study if the effects of
the two treatments were related to their hypotensive action or
to their action as suppressors of the renin-angiotensin system.
Therefore, the aim of the present study was to compare the
effects of an ACE inhibitor with an antihypertensive regimen
which does not suppress the renin-angiotensin system. The
present study compares the ACE inhibitor, perindopril, with
triple therapy (hydralazine, reserpine and hydrochiorothiazide).
Serial measurements of glomerular filtration rate were per-
formed to determine if effects on urinary albumin excretion
were paralleled by changes in renal function, since it has been
suggested that the progression of renal disease may be linked to
the process of hyperfiltration [5].
Methods
Research design
Male spontaneously hypertensive rats (SHR, Okamoto
strain) weighing between 200 and 250 grams, aged eight weeks,
were injected intravenously with streptozocin at a dose of 45
mg/kg after an overnight fast. Only animals with blood glucose
levels >15 mmol/liter one week after injection of streptozocin
were included in the study. Diabetic SHR were randomized to
receive either no treatment, perindopril (6 mg/liter in drinking
water) or triple therapy [hydralazine (50 mg/liter), reserpine (4
mg/liter) and hydrochlorothiazide (30 mg/liter) all administered
in drinking water]. All animals were caged in groups of four and
were given rat chow containing 20% protein. Ultralente insulin
(Novo Industri A/S, Copenhagen, Denmark), 2 units per day,
was administered to all groups to reduce mortality. Measure-
ments of body weight, systolic blood pressure and glycemic
control were performed at 0, 4, 8, 12 and 16 weeks. Plasma
renin activity was measured in diabetic SHR at 0, 1, 4 and 16
weeks of diabetes. In a subgroup of animals, plasma angiotensin
converting enzyme (ACE) activity was measured at weeks I
and 16. Glomerular filtration rate was measured at 0, 4 and 12
weeks. Urinary albumin excretion was measured at weeks 0, 8,
12 and 16 after urine had been collected for 24 hours in
metabolic cages (Iffa Credo, L'Arbresele, France). Daily food
consumption was measured when animals were in the metabolic
cages.
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Methods
Systolic blood pressure was measured via indirect tail-cuff
plethysmography in preheated conscious rats [6]. Serum glu-
cose was measured by a glucose oxidase technique [7]. Gly-
cated hemoglobin (HbA1) was measured by an automated
HPLC technique (Biorad Diamat, Richmond, California, USA)
as previously described [8]. Plasma renin activity was measured
by radioimmunoassay [9]. Plasma ACE activity was measured
by a fluorometric technique by measuring histidyl-leucine (HL)
production from incubation of plasma with hippuryl-histidyl-
leucine [10]. Since plasma ACE concentration may be induced
during long-term ACE inhibition, further assessment of inhibi-
tion of the renin-angiotensin system was undertaken by com-
paring plasma ACE activity, corrected for protein content, and
assayed by the Lowry method [11], before and after dialysis
[12]. Dialysis was performed for three days against 1 LM EDTA
to remove the active drug, perindoprilat, followed by two days
of dialysis against 50 tM zinc at 4°C to reconstitute ACE
binding activity. Urinary albumin excretion was measured by
radioimmunoassay [2]. The inter-assay coefficient of variation
was 9.0% (N = 6) at a concentration of 180 nglml and the
detection limit of the assay was 31.2 ng/ml. Glomerular filtration
rate was measured by a single-injection isotopic technique devel-
oped in our laboratory [8]. This technique can be performed in a
serial manner over several months in conscious rats. In brief,
99mtechnetiumdiethylene triamine penta-acetic acid (DTPA) was
injected via tail vein and blood was sampled after 43 minutes.
Plasma radioactivity was measured and compared with a refer-
ence made at the time of injection. The glomerular filtration rate
was then calculated from the measurements of plasma radioactiv-
ity as previously described [8]. The coefficient of variation of the
method is 7.4% (N = 12). The volume of distribution used for
calculation of GFR was 28% as has been previously determined in
moderately controlled diabetic rats [8].
Statistical analysis
Urinary albumin excretion was analyzed after logarithmic
transformation. Data are shown as mean SEM except for
urinary albumin excretion data which are shown as geometric
means and tolerance factors. Comparisons of normally distrib-
uted variables among the different groups over the study period
were performed by analysis of variance with or without re-
peated measurements using the Statview SE and Graphics
Program (Brainpower, Calabasas, California, USA) on a Mac-
intosh SE personal computer (Apple, Cupertino, California,
USA). Comparisons between group means were performed by
Fisher's protected least-significant difference test [13].
Results
Blood pressure
Of the 36 animals induced with diabetes in each group, 21
untreated (U), 20 triple therapy (TT) and 15 perindopril (P)
treated rats survived 16 weeks, the majority of deaths occurring
in the first four weeks of diabetes. Systolic blood pressure was
significantly reduced in the P and TT groups when compared to
untreated diabetic SHR (mean systolic blood pressure on treat-
ment; U 205 2, TT 145 1, P 146 1 mm Hg, F = 318, P <
0.001; Fig. 1). There was no significant difference between the
P and TT groups.
Glycemic control and body weight
There was no significant difference in mean serum glucose
among the three groups (serum glucose weeks 4 to 16, U 31.6
1.3, TT 31.2 1.3, P 30.7 1.8 mM). At week 16, plasma
glucose levels were similar among the three groups (U 33.3
1.7; TT 29.4 2.2, P 29.6 2.6mM). HbAIC levels were similar
in all three groups (U 3.8 0.1%; TT 3.7 0.2%; P 3.6
0.1%). There was no significant difference in weight gain among
the three groups (Fig. 2). Food consumption was similar among
the three groups (U 25 3; TT 25 2; P 28 I g/24 hr).
Measurements of the renin-angiotensin system
There were no significant differences in plasma renin activity
(PRA) among the three groups before induction of diabetes
(Table 1). After one week of diabetes there was a significant rise
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Fig. 1. Data are shown as mean SEM in untreated (0, N = 21), triple
therapy (•, N = 20) and perindopril treated diabetic rats (, N = 15).
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Fig. 2. Data are shown as mean SEM in untreated (0), triple therapy(•) and perindopril treated diabetic rats (z).
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in TT and P treated groups were not significantly different from
each other but the increase in PRA when compared to the
untreated group persisted at weeks 4 and 16 (Table 1). Plasma
ACE activity was significantly reduced in the perindopril
treated rats (U 59 7, N 8; TT 49 5, N = 10; P25 4fl
HL/ml/min, N = 13; P < 0.01, P versus other groups). As
previously outlined, long-term perindopril therapy may under-
estimate the degree of ACE inhibition. After dialysis of penn-
doprilat from plasma, ACE inhibition was calculated to be 87
2%. ACE inhibition was sustained over the study period but
was significantly less at week 16 when compared to week I
(week 1, 92 1 vs. week 16, 82 4%, P < 0.05).
Glomerular filtration rate and urinary albumin excretion
There was no significant difference in GFR among the three
groups at week 0 (Fig. 3). Induction of diabetes was associated
with a significant increase in GFR (F 52.6, P < 0.01) in all
groups. At week 4, TT rats had lower GFR than P treated rats
(P < 0.025), but this was not significantly different from values
in untreated rats.
Both drug therapies significantly reduced urinary albumin
excretion when compared to untreated rats (Fig. 4). There was
no significant difference in albuminuria between P and TT
treated rats. Similar findings were observed if albuminuria data
were corrected for GFR (week 12, U 2.8 0.7; TT 0.9 0,1, P
<0.01 vs. U; P0.9 0.1 mg mm/mi . 24 hr. P < 0.05 vs. U).
Discussion
In the present study we have compared the ACE inhibitor,
perindopril, to triple therapy in diabetic SHR. Both hypotensive
regimens equally reduced systemic blood pressure and retarded
the increase in urinary albumin excretion over the 16 week
study period (Fig. 4). These similar effects occurred in spite of
apparently opposite effects on the renin-angiotensin system.
The ACE inhibitor reduced plasma angiotensin II due to sup-
pression of plasma ACE as was observed in the present study.
The rise in plasma renin activity represented a compensatory
response [141!. The triple therapy regimen which included a
diuretic and hydralazine, stimulating plasma renin activity, and
leading to an increase in plasma angiotensin 11 levels 14]. It is
possible that the difference in GFR observed between triple
therapy and perindopril treated rats after 12 weeks of diabetes
may have reflected differences in plasma or intrarenal angioten-
sin II levels since angiotensin II is a potent renal vasoconstric-
tor [15]. However, it is important to note that GFR was not
different in the groups treated with antihypertensive therapy
when compared to untreated animals.
Recently, further studies have been performed to determine if
ACE inhibitors have a specific effect independent of their
hypotensive action. Fabris, Jackson and Johnston administered
the ACE inhibitor, ramipnil, to uninephrectomized diabetic
SHR in the setting of normal and high salt intake [16]. Rats
which received high salt intake and ramipril had no reduction in
blood pressure and no effect on urinary albumin excretion,
Tab'e [. Plasma renin activity (ng/ml/hr)
Group Week 0 Week 1 Week 4 Week 16
Untreated 7.5 ÷ 1.0 7.8 1.2 8.0 1.4 8.0 1.5
Triple therapy 6.0 0.8 19.1 2.3a 21.3 2.8 20.2 2.6'
Perindopril 7.8 1.0 21.5 3,7a 19.8 3.3' 18.3 5.3k'
Data are presented as mean SEM.

















Fig. 4. Data are shown for albuminuria as geometric means and
tolerance factors in untreated (0, N =20), triple therapy (•, N = 19)
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despite demonstrable ACE inhibition in plasma and the kidney.
Other studies concentrating on the possibility that ACE inhib-
itors confer a specific benefit in renal disease have used the
model of subtotal nephrectomy [17, 18]. In studies performed
by Anderson, Rennke and Brenner in the Munich-Wistar rat the
effect of triple therapy and the ACE inhibitor, enalapril, ap-
peared to differ with respect to their effects on proteinuria and
glomerulosclerosis [17]. The ACE inhibitor appeared to be
more effective than triple therapy and the beneficial effect was
attributed to the ability of ACE inhibitors to normalize intra-
glomerular pressure. In contrast, intraglomerular pressure was
not reduced with triple therapy. However, in a more recent
study in rats after subtotal nephrectomy the effects on glomer-
ular structure were equivalent in triple therapy and enalapril
treated groups [18]. This renoprotective effect occurred despite
the failure of triple therapy to reduce intraglomerular pressure.
The differences in the results between the two studies may
relate to the difference in doses of the individual drugs in the
triple therapy regimen administered in both studies [17, 18].
With respect to diabetes, Anderson et al have compared
captopril to triple therapy in normotensive streptozotocin dia-
betic Munich Wistar rats [19]. In these studies there appeared to
be an effect of both regimens in retarding the development of
albuminuria and focal glomerulosclerosis over the 70-week
study period. However, captopril appeared to be more effective
than triple therapy, particularly in the latter half of the study
period. The advantage of captopril over triple therapy was
attributed to the ability of captopril to normalize the elevated
glomerular capillary pressure in the diabetic rats. However,
both triple therapy and captopril treatment normalized glomer-
ular pressure in early studies 6 to 10 weeks after induction of
diabetes, and the disparate effects of the two regimens on renal
hemodynamics were apparent only in later studies performed
after one year of diabetes. This makes it difficult to determine if
the changes in renal hemodynamics were primary or secondary
to the development of glomerular damage in the diabetic rats.
However, there are several clues in that study [191 to indicate
that the changes in intraglomerular pressure observed in dia-
betic rats treated with triple therapy were not secondary to
glomerular damage. Firstly, effects on urinary albumin excre-
tion were already observed in the first six months of study.
Secondly, histological assessment of the kidneys of these rats
revealed that the majority of glomeruli were not sclerosed.
A recent study by our group comparing the ACE inhibitor,
perindopril, to triple therapy in diabetic Sprague-Dawley rats
suggested a similar efficacy of both treatments with respect to
preventing diabetes associated increases in urinary albumin
excretion [201. The differences between the two studies may
relate to differences in rat strains. It has previously been shown
that the Munich Wistar rat may be more susceptible to focal
segmental glomerulosclerosis [211, and it is possible that some
of the renoprotective effects of ACE inhibition may relate to
glomerular injury unrelated to diabetes. It has been observed
that rat strain is an important determinant of the functional and
structural response of the kidney to induction of diabetes.
Induction of diabetes in the DA rat results in less proteinuria
and mesangial expansion than in the Lewis rat [221. In our own
studies, the induction of diabetes was associated with the
development of more albuminuria in the Sprague-Dawley than
the Wistar Kyoto rat [2, 201. Moreover, the spontaneously
diabetic BB rat does not develop mesangial expansion but has
glomerular basement membrane thickening [23, 24]. A recent
study has suggested that the reduction in glomerulosclerosis
with ACE inhibition also occurs in non-diabetic aging rats [25].
Our own studies confirm that antihypertensive agents influence
albuminuria and glomerular ultrastructural parameters in the
absence of diabetes [261. Therefore, the specificity of the
actions of these antihypertensive agents in diabetes needs to be
questioned. Another factor to consider is the different duration
of the two studies [19, 201. The effects of captopril in the
Munich Wistar rats were most apparent after 32 weeks of
diabetes [191, and this may relate to the effects of ACE
inhibition on age-related rather than diabetes-related glomerular
injury [25].
Our own studies have evaluated the role of systemic hyper-
tension on functional and structural features of experimental
diabetic nephropathy [2]. Streptozotocin diabetes was induced
in both normotensive Wistar Kyoto rats and their hypertensive
counterparts, SHR. Not only was there a dramatic increase in
urinary albumin excretion with the addition of hypertension to
diabetes, but there were increases in glomerular basement
membrane thickening and glomerular volume. Effects on
mesangial expansion were more modest. Further studies per-
formed using antihypertensive therapy have confirmed that
many of the glomerular ultrastructural parameters are linked to
the presence of hypertension [3, 26]. In particular, antihyper-
tensive therapy either with enalapril or with hydralazine and
metoprolol was able to reduce glomerular basement membrane
thickness and glomerular volume whereas mesangial expansion
was not influenced by these agents. It is interesting to note that
studies which have concentrated on the effects of glycemic
control rather than antihypertensive therapy have tended to
show different results with respect to glomerular ultrastructural
abnormalities. Despite similar beneficial effects on urinary
albumin excretion glomerular basement membrane thickening
was not prevented by pancreatic transplantation whereas
mesangial expansion was reversed [27—29]. This may suggest
that the various glomerular ultrastructural abnormalities ob-
served in experimental diabetes are influenced by different
factors. Glomerular basement membrane thickening may be
more strongly related to systemic or glomerular hypertension
whereas mesangial expansion may be more closely linked to
metabolic factors.
In our previous experimental studies, glomerular basement
membrane thickening and glomerular volume were linked to the
presence of hypertension [2, 3]. It has been suggested that
glomerular rather than systemic hypertension may be the major
determinant of glomerular ultrastructural damage. To explore
this possibility, models in which glomerular but not systemic
hypertension are evident, have been investigated. These in-
clude models in which dietary protein intake has been modified
[30, 31]. For example, reduction in protein intake from 12 to 6%
in diabetic rats was associated with a reduction in intraglomer-
ular pressure, decreased albuminuria as well as reduced gb-
merular basement membrane thickness 130]. Furthermore,
studies performed by Mauer et al have shown that increases in
protein intake from 20 to 50% are associated not only with
increases in urinary albumin excretion but also with alterations
in glomerular ultrastructural parameters such as gbomerular
basement membrane thickness and glomerular volume [31].
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The mechanism by which antihypertensive agents ameliorate
glomerular damage remains controversial. Two major pathways
that have been considered as important in the progression of
renal injury, include glomerular hypertrophy [32] and glomeru-
lar hyperfiltration [33]. Both these mechanisms could be rele-
vant in diabetes. From a hemodynamic perspective, there is
evidence of increases in renal plasma flow, glomerular filtration
rate and intraglomerular pressure in experimental diabetes [34].
With respect to glomerular hypertrophy, diabetes is associated
with renal hypertrophy which includes increases in all compo-
nents of the kidney including the glomerulus [351. The link
between renal hypertrophy and glomerular injury has recently
been evaluated in various animal models of renal injury [18, 321.
These studies have suggested that glomerular hypertrophy is
closely related to the subsequent development of glomerulo-
sclerosis, although diabetes has not been specifically evaluated.
It has been speculated that in hypertension there is an
increase in local wall tension with an associated increase in
physical forces leading to cellular hypertrophy and extracellular
matrix synthesis [36]. In diabetes there is afferent vasodilatation
[341 and this would result in direct transmission of systemic
blood pressure to the glomerulus. This would result in increased
glomerular injury via a hemodynamic effect or an effect on
factors which influence renal growth. The mechanism of action
of antihypertensive agents in retarding glomerular injury re-
mains unclear, These agents may reduce intraglomerular pres-
sure and could therefore be acting favorably on glomerular
hemodynamics. This mechanism has been reported for the
action of ACE inhibitors on the glomerular microcirculation
[19]. An additional possibility is that antihypertensive agents
act as inhibitors of renal growth by influencing DNA synthesis.
Such an effect has been observed with hydralazine on aortic
smooth muscle cells [37] and more recently with enalapril on
glomerular cells [38].
The present study extends previous findings by our group
suggesting that various classes of antihypertensive drugs have a
beneficial effect on the development of albuminuria in experi-
mental diabetes. At this stage, one must be cautious in applying
the results of these studies in diabetic SHR to the normotensive
context. The findings from these experimental studies may be of
relevance to nephropathy in humans and assist in determining
the direction of clinical trials. Many of these trials are now in
progress and confirm that the findings obtained in rodents,
although not able to be directly applied to humans, are helpful
in the initial evaluation of potential mechanisms and therapies
for diabetic renal disease.
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